Oronzo Brunetti, Giuseppe Aprile, Paolo Marchetti1, Enrico Vasile2, Andrea Casadei Gardini3, Mario Scartozzi4, Sandro Barni5, Sara Delfanti6, Fernando De Vita7, Francesco Di Costanzo8, Michele Milella9, Chiara Alessandra Cella10, Rossana Berardi11, Ivana Cataldo12, Aldo Scarpa12, Debora Basile13, Federica Mazzuca1, Giusi Graziano14, Antonella Argentiero, Daniele Santini15, Michele Reni16, Stefano Cascinu17, Nicola Silvestris. 1. Medical Oncology Unit, Sant'Andrea Hospital, University of Rome La Sapienza, Rome. 2. Medical Oncology Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa. 3. Department of MedicalOncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola. 4. Medical Oncology Unit, University of Cagliari, Cagliari. 5. Medical Oncology Unit, ASST Bergamo Ovest, Treviglio. 6. Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia. 7. Medical Oncology Unit, II University of Naples, Naples. 8. Medical OncologyUnit, Azienda Ospedaliero-Universitaria Careggi, Florence. 9. Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome. 10. Division of Gastrointestinal and Neuroendocrine Tumors, IEO, Milan. 11. Medical Oncology Unit, Università Politecnica Marche - Ospedali Riuniti Ancona, Ancona. 12. Department of Pathology and Diagnostics, University of Verona, ARCNET, Verona. 13. Department of Medical Oncology, University and General Hospital, Udine. 14. Scientific Direction, Cancer Institute "Giovanni Paolo II," Bari. 15. Medical Oncology Unit, University Campus Biomedico, Rome. 16. Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan. 17. Modena Cancer Center, University of Modena and Reggio Emilia, Azienda Ospedaliera-Universitaria di Modena, Modena, Italy.
Abstract
OBJECTIVES: Two issues were put forth by clinicians in the management of the advanced stages of rare variants of pancreatic ductal adenocarcinoma and other exocrine histotypes with peculiar clinical and pathological features: Do chemotherapy regimens recommended in pancreatic ductal adenocarcinoma patients have a clinical activity in rare pancreatic tumors? Or should other chemotherapy combinations be considered in this subset of patients? METHODS: We conducted a multicenter retrospective study that collected data from 2005 to 2016 at 14 Italian cancer centers with the aim to evaluate tumor response and time to progression for first- and second-line and overall survival. RESULTS: Of approximately 4300 exocrine pancreatic cancer patients, 79 advanced cases affected by rare histological types were identified, with pancreatic acinar cell cancer (n = 23), pancreatic adenosquamous cancer (n = 16), and mucinous cystic neoplasm with an associated invasive mucinous cystadenocarcinoma (n = 15) most represented. Survival analyses for each subgroup in relation with the different chemotherapy regimens showed the lack of statistical significance correlations. CONCLUSIONS: Because of the lack of clinical trials in patients affected by these rare pancreatic histotypes, only their molecular classification would help clinicians in future therapeutic choice.
OBJECTIVES: Two issues were put forth by clinicians in the management of the advanced stages of rare variants of pancreatic ductal adenocarcinoma and other exocrine histotypes with peculiar clinical and pathological features: Do chemotherapy regimens recommended in pancreatic ductal adenocarcinomapatients have a clinical activity in rare pancreatic tumors? Or should other chemotherapy combinations be considered in this subset of patients? METHODS: We conducted a multicenter retrospective study that collected data from 2005 to 2016 at 14 Italian cancer centers with the aim to evaluate tumor response and time to progression for first- and second-line and overall survival. RESULTS: Of approximately 4300 exocrine pancreatic cancerpatients, 79 advanced cases affected by rare histological types were identified, with pancreatic acinar cell cancer (n = 23), pancreatic adenosquamous cancer (n = 16), and mucinous cystic neoplasm with an associated invasive mucinous cystadenocarcinoma (n = 15) most represented. Survival analyses for each subgroup in relation with the different chemotherapy regimens showed the lack of statistical significance correlations. CONCLUSIONS: Because of the lack of clinical trials in patients affected by these rare pancreatic histotypes, only their molecular classification would help clinicians in future therapeutic choice.
Authors: Nebojsa Skorupan; Mehwish I Ahmad; Seth M Steinberg; Jane B Trepel; Derek Cridebring; Haiyong Han; Daniel D Von Hoff; Christine Alewine Journal: Future Oncol Date: 2022-05-10 Impact factor: 3.674
Authors: Mariacristina Di Marco; Riccardo Carloni; Stefania De Lorenzo; Cristina Mosconi; Andrea Palloni; Elisa Grassi; Daria Maria Filippini; Angela Dalia Ricci; Alessandro Rizzo; Alessandro Di Federico; Donatella Santini; Daniela Turchetti; Claudio Ricci; Carlo Ingaldi; Laura Alberici; Francesco Minni; Rita Golfieri; Giovanni Brandi; Riccardo Casadei Journal: World J Gastrointest Oncol Date: 2020-12-15
Authors: Elena Busch; Simon Kreutzfeldt; Abbas Agaimy; Gunhild Mechtersheimer; Peter Horak; Benedikt Brors; Barbara Hutter; Martina Fröhlich; Sebastian Uhrig; Philipp Mayer; Evelin Schröck; Albrecht Stenzinger; Hanno Glimm; Dirk Jäger; Christoph Springfeld; Stefan Fröhling; Stefanie Zschäbitz Journal: Cold Spring Harb Mol Case Stud Date: 2020-08-25